<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496262</url>
  </required_header>
  <id_info>
    <org_study_id>BI3023_2001</org_study_id>
    <nct_id>NCT00496262</nct_id>
  </id_info>
  <brief_title>Human Fibrinogen - Pharmacokinetics</brief_title>
  <official_title>Pharmacokinetics of Haemocomplettan® P in Subjects With Congenital Fibrinogen Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and
      clot strength (maximum clot firmness [MCF]) in subjects with congenital fibrinogen
      deficiency. MCF was measured to demonstrate the functional activity of replacement fibrinogen
      when a fixed dose of human fibrinogen concentrate was administered.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Clot Firmness (MCF)</measure>
    <time_frame>Pre-infusion and 1 hour post-infusion</time_frame>
    <description>MCF is a functional parameter that depends on the activation of coagulation, the fibrinogen content of the sample (in plasma), and the polymerization and crosslinking of the fibrin network. MCF was determined by rotational thromboelastometry (ROTEM) testing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (t1/2)</measure>
    <time_frame>0.5 hours to 13 days post-infusion</time_frame>
    <description>t1/2 for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax)</measure>
    <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
    <description>Cmax for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) Standardized for 70 mg/kg Body Weight Dose</measure>
    <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
    <description>AUC for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (Cl)</measure>
    <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
    <description>Cl for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRT)</measure>
    <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
    <description>MRT for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
    <description>Vss for fibrinogen activity was determined from samples taken at 11 timepoints during the specified time frame.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incremental In Vivo Recovery (IVR)</measure>
    <time_frame>Pre-infusion to 4 hours post-infusion</time_frame>
    <description>Maximum fibrinogen activity increase in plasma per mg/kg dosed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Classical In Vivo Recovery (IVR)</measure>
    <time_frame>Pre-infusion to 4 hours post-infusion</time_frame>
    <description>Maximum fibrinogen activity increase in plasma times plasma volume per mg/kg dose</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Fibrinogen Deficiency</condition>
  <arm_group>
    <arm_group_label>Human Fibrinogen Concentrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human Fibrinogen Concentrate</intervention_name>
    <description>Single intravenous infusion of 70 mg/kg body weight</description>
    <arm_group_label>Human Fibrinogen Concentrate</arm_group_label>
    <other_name>Haemocomplettan® P</other_name>
    <other_name>RiaSTAP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged ≥ 6 years

          -  Documented congenital fibrinogen deficiency: fibrinogen deficiency manifested as
             afibrinogenemia with plasma fibrinogen activity and antigen at screening undetectable
             (i.e. &lt; 20 mg/dL)

          -  Informed consent signed by subject or legal guardian

        Exclusion Criteria:

          -  Presence or history of hypersensitivity to Human Fibrinogen Concentrate or human
             plasma proteins,

          -  Presence or history of deep vein thrombosis, pulmonary embolism, or arterial
             thrombosis

          -  Acute bleeding

          -  History of esophageal varicose bleeding

          -  End stage liver disease (i.e. Child-Pugh score B or C)

          -  Planned major surgery with a need for blood transfusion during the PK blood sampling
             period

          -  Polytrauma within 1 year prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Program Director, Clinical R&amp;D</last_name>
    <role>Study Director</role>
    <affiliation>CSL Behring</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074-9308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Cagliari</city>
        <zip>09100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Napoli</city>
        <zip>80122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Palermo</city>
        <zip>90134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Contact CSL Behring for facility details</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.cslbehring.com/clinical-trials/contact-us.htm?registryRefNum=NCT00496262&amp;registryName=ctgov</url>
    <description>Click here to request more information about this study</description>
  </link>
  <results_reference>
    <citation>Manco-Johnson MJ, Dimichele D, Castaman G, Fremann S, Knaub S, Kalina U, Peyvandi F, Piseddu G, Mannucci P; FIBRINOGEN CONCENTRATE STUDY GROUP. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost. 2009 Dec;7(12):2064-9. doi: 10.1111/j.1538-7836.2009.03633.x. Epub 2009 Oct 5.</citation>
    <PMID>19804533</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <results_first_submitted>May 19, 2009</results_first_submitted>
  <results_first_submitted_qc>May 19, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 10, 2009</results_first_posted>
  <last_update_submitted>July 27, 2016</last_update_submitted>
  <last_update_submitted_qc>July 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital fibrinogen deficiency</keyword>
  <keyword>Fibrinogen concentrate</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Thrombelastography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afibrinogenemia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled at study sites in the USA and Italy.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Human Fibrinogen Concentrate</title>
          <description>All enrolled subjects received a single IV infusion of 70 mg/kg body weight of human fibrinogen concentrate.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Human Fibrinogen Concentrate</title>
          <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.5" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;16 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥16 to &lt; 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Clot Firmness (MCF)</title>
        <description>MCF is a functional parameter that depends on the activation of coagulation, the fibrinogen content of the sample (in plasma), and the polymerization and crosslinking of the fibrin network. MCF was determined by rotational thromboelastometry (ROTEM) testing.</description>
        <time_frame>Pre-infusion and 1 hour post-infusion</time_frame>
        <population>All subjects in the intention to treat (ITT) population. The ITT population included all subjects who received any portion of any infusion of human fibrinogen concentrate. (Note: 2 subjects in the ITT population had missing MCF data; the change from baseline MCF was entered as 0.0 for these subjects.)</population>
        <group_list>
          <group group_id="O1">
            <title>Pre-infusion</title>
            <description>≤ 2 hours before start of infusion</description>
          </group>
          <group group_id="O2">
            <title>1 Hour Post-infusion</title>
            <description>1 hour after end of infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Clot Firmness (MCF)</title>
          <description>MCF is a functional parameter that depends on the activation of coagulation, the fibrinogen content of the sample (in plasma), and the polymerization and crosslinking of the fibrin network. MCF was determined by rotational thromboelastometry (ROTEM) testing.</description>
          <population>All subjects in the intention to treat (ITT) population. The ITT population included all subjects who received any portion of any infusion of human fibrinogen concentrate. (Note: 2 subjects in the ITT population had missing MCF data; the change from baseline MCF was entered as 0.0 for these subjects.)</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="8.9" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This is an open-label study with statistical comparison between MCF pre-infusion and 1 hour post-infusion.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>2-sided, 1-sample t-test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>8.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <estimate_desc>The entire ITT population was used for a conservative analysis of the mean change in MCF. The mean change was set to 0 for any subject with missing MCF data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (t1/2)</title>
        <description>t1/2 for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
        <time_frame>0.5 hours to 13 days post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (t1/2)</title>
          <description>t1/2 for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax)</title>
        <description>Cmax for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
        <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax)</title>
          <description>Cmax for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve (AUC) Standardized for 70 mg/kg Body Weight Dose</title>
        <description>AUC for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
        <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC) Standardized for 70 mg/kg Body Weight Dose</title>
          <description>AUC for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>hour*mg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.3" spread="24.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance (Cl)</title>
        <description>Cl for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
        <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance (Cl)</title>
          <description>Cl for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>mL/hour/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRT)</title>
        <description>MRT for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
        <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRT)</title>
          <description>MRT for fibrinogen activity was determined from samples taken at 12 timepoints during the specified time frame.</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8" spread="20.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State (Vss)</title>
        <description>Vss for fibrinogen activity was determined from samples taken at 11 timepoints during the specified time frame.</description>
        <time_frame>Pre-infusion to 13 days post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State (Vss)</title>
          <description>Vss for fibrinogen activity was determined from samples taken at 11 timepoints during the specified time frame.</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="7.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incremental In Vivo Recovery (IVR)</title>
        <description>Maximum fibrinogen activity increase in plasma per mg/kg dosed</description>
        <time_frame>Pre-infusion to 4 hours post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental In Vivo Recovery (IVR)</title>
          <description>Maximum fibrinogen activity increase in plasma per mg/kg dosed</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>mg/dL increase per mg/kg body weight</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" lower_limit="1.3" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Classical In Vivo Recovery (IVR)</title>
        <description>Maximum fibrinogen activity increase in plasma times plasma volume per mg/kg dose</description>
        <time_frame>Pre-infusion to 4 hours post-infusion</time_frame>
        <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
        <group_list>
          <group group_id="O1">
            <title>Human Fibrinogen Concentrate</title>
            <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
          </group>
        </group_list>
        <measure>
          <title>Classical In Vivo Recovery (IVR)</title>
          <description>Maximum fibrinogen activity increase in plasma times plasma volume per mg/kg dose</description>
          <population>The pharmacokinetic analysis population (PK PP) included all subjects who received &gt;90% of the infusion and who also had sufficient data for a reliable PK analysis (n=14).</population>
          <units>% of expected increase in fibrinogen</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8" lower_limit="52.5" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Human Fibrinogen Concentrate</title>
          <description>Includes all subjects who received any portion of the infusion of human fibrinogen concentrate.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator must provide a copy of any results communication to the sponsor for review at least 30 days prior to public release. The sponsor may request any changes necessary to prevent forfeiture of patent rights to data not in the public domain. For a multi-center study, the investigator must wait (i) at least 1 year after the study is completed at all sites or (ii) until notified by the sponsor that no multi-center publication is planned before seeking publication review.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Program Director, Clinical R&amp;D</name_or_title>
      <organization>CSL Behring</organization>
      <phone>Use email contact.</phone>
      <email>clinicaltrials@cslbehring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

